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ABSTRACT
Background: Early intervention in adult asthma has been evaluated mostly with regard to symptoms, respira-
tory function and airway hyperresponsiveness, and has rarely been evaluated with regard to airway inflamma-
tion. Further, no clinical data concerning prevention of remodeling by anti-inflammatory therapy have been re-
ported. The anti-inflammatory activities of an inhaled steroid and a leukotriene receptor antagonist were com-
pared using sputum induced by inhaled hyperosmotic NaCl solution, and the usefulness of anti-inflammatory
treatment for mild intermittent asthma (step 1) was investigated.
Methods: The subjects of the study were patients with mild intermittent asthma (step 1) who had not received
steroid treatment and had only been treated with inhaled β2-stimulants as needed. The subjects were divided
into two groups : one group received 400 µgday of budesonide (BUD group ; n = 15) and the other group re-
ceived 10 mgday of montelukast (MK group ; n = 12). The anti-inflammatory activities of BUD and MK were
compared by examining respiratory function, exhaled nitric oxide (ENO) concentrations, airway hyperrespon-
siveness (acetylcholine provocation test) and the sputum induced by inhalation of hyperosmotic NaCl solution
at three time points, i.e., before, 1 month after, and 6 months after the start of treatment.
Results: It was shown that even in mild intermittent asthma (step 1) the levels of ENO and sputum eosinophil
ratio were elevated, indicating that airway inflammation was clearly present and that airway hyperresponsive-
ness was elevated. The effects of BUD and MK in improving ENO and sputum eosinophil ratio were almost the
same. However, airway hyperresponsiveness in both groups were not significantly improved after 1 and 6
months of treatment．
Conclusions: Anti-inflammatory treatment is necessary even for mild intermittent asthma (step 1). We believe
that early intervention with anti-inflammatory drugs is important for the prevention of airway remodeling, exacer-
bation of disease and progression to intractable asthma. Either of the two types of drugs, low-dose inhaled ster-
oids or leukotriene receptor antagonists , can be selected as anti-inflammatory drugs for mild intermittent
asthma．
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INTRODUCTION
Bronchial asthma is defined by three characteristics,
i.e., reversible airway constriction, enhancement of
airway hyperresponsiveness and airway inflamma-
tion, of which the latter is considered an important
factor in bronchial asthma.1 The airway inflammation
seen in bronchial asthma is chronic allergic inflam-
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p valueMK group
BUD400 
group
1215Ｎ
0.19395/710/5Male/Female
0.909735.6±14.436.2±12.8Age, years
0.72158/49/6Atopy/Non-atopy
0.579613.3±14.010.4±12.8
Duration of asthma
 (years)
0.241783.6±8.7 79.1±10.4FEV1.0/FVC ratio (%)
0.209694.5±9.9 88.8±12.5
FEV1.0, as percent of 
the predicted value
Table 1　Characteristics of the study subjects
mation characterized by injury of airway epithelia due
to the infiltration of inflammatory cells consisting
mainly of eosinophils. Allergy, infections with viruses
etc. and various environmental factors are involved in
the etiology of chronic inflammation. These acquired
factors induce infiltration into airways and activation
of inflammatory cells such as eosinophils, Th2 cells
and neutrophils to release inflammatory mediators
and cytokines. The interaction of these inflammatory
mediators and cytokines then causes airway inflam-
mation leading to injury of airway epithelia. It is be-
lieved that the injury of airway epithelia combined
with constriction of airway smooth muscles leads to
enhancement of airway hyperresponsiveness. In pa-
tients with bronchial asthma, which is a chronic dis-
ease, even during periods when there are no asthma
attacks, the numbers of eosinophils in bronchoalveo-
lar lavage fluid and sputum and the level of eosinophil
cationic protein (ECP) are higher than in healthy sub-
jects, indicating the presence of airway inflammation.
The degree of airway inflammation and that of airway
hyperresponsiveness correlate well , and airway in-
flammation is therefore considered the cause of air-
way hyperresponsiveness.2-6
In guideline (1) of GINA2002 (Global Initiative for
Asthma 2002), it is noted that, for the treatment of
chronic adult asthma of mild intermittent type (step
1), giving β2-stimulants alone only during periods of
disease exacerbation is sufficient and that regular
anti-inflammatory treatment using inhaled steroids
etc. is not necessary. However, it has been reported
that, even during periods when there are no asthma
attacks in patients with mild intermittent asthma, air-
way inflammation exists.7 Therefore , it is expected
that, if anti-inflammatory therapy for mild intermittent
asthma is not started early, exacerbation of airway in-
flammation will occur in some patients , leading to
more frequent attacks of asthma, progression of air-
way remodeling and more severe and intractable
asthma．
The subjects of the present study were patients
with mild intermittent asthma who did not have
asthma attacks at the time of the study and who had
not received regular anti-inflammatory treatment
such as inhaled steroids and had received only in-
haled β2-stimulants as needed. The measurement of
exhaled nitric oxide concentration, the airway hyper-
responsiveness test and examination of sputum in-
duced by inhalation of hyperosmotic NaCl solution
were carried out before the treatment was started.
Then, inhaled steroid and leukotriene receptor an-
tagonist were prescribed . After 1 month and 6
months of treatment , similar tests were performed
and the inhibitory effects of the two drugs on airway
inflammation and airway hyperresponsiveness were
compared and the usefulness of the anti-inflammatory
treatment and early intervention for mild intermittent
asthma were examined. This study was approved by
the ethics committee of National Minami-Fukuoka
Hospital and all the participants signed the patient in-
formed consent forms．
METHODS
SUBJECTS
The subjects in this study were 27 outpatients with
mild intermittent asthma who visited the Department
of Allergy at National Minami-Fukuoka Hospital .
None of them had received regular anti-inflammatory
treatment such as inhaled steroids. They had been
treated only with inhaled β2-stimulants as needed .
The diagnosis and judgment of severity of asthma
were performed according to the guidelines of GINA
2002. There were no asthma attacks in any of the pa-
tients at the time of clinical examination. The subjects
were randomly divided into two groups : a budeson-
ide 400 μgday group (BUD group ; n = 15) and mon-
telukast 10 mgday group (MK group ; n = 12). There
were more male patients in the BUD group and there
were more female patients in the MK group. There
were no significant differences in age, presence of
atopynon-atopy or duration of asthma between the
two groups, and respiratory function was normal in
both groups. No significant differences in FEV1FVC
ratio and FEV1, as percent of the predicted value,
were found between the two groups before treatment
（Table 1).
STUDY DESIGN
Before the treatment, measurement of exhaled nitric
oxide concentration , measurement of flow-volume
curves, the airway hyperresponsiveness test (acetyl-
choline provocation test) and examination of sputum
induced by inhaled hyperosmotic NaCl solution were
carried out in this order, and then treatment with 400
μgday of budesonide or 10 mgday of montelukast
was started. After 1 month and 6 months of treat-
ment, similar examinations were performed and the
inhibitory effects of the two drugs on airway inflam-
mation and airway hyperresponsiveness were com-
pared．
Inhaled β2-stimulant was withheld for 48 hours
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Fig. 1　Exhaled nitric oxide (ENO) concentration, PC20 and sputum eosinophil ratio in mild intermitent asthma (step 1) 
(Pretreatment: n = 27). Even in cases of mild intermitent asthma, exhaled nitric oxide (ENO) concentration and sputum eosino-
phil ratio were elevated. Airway inflammation and elevated airway hyperesponsiveness were present. PC20 is expressed as 
logPC20.
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prior to the clinical examinations, and no subjects re-
ceived other asthma medications, including inhaled
or oral steroid therapy．
After confirming that FEV1 was more than 80% of
the predicted value,a blood sample was collected for
the measurement of IgE- radioimmunosorbent test
(RIST) and IgE-RAST. The provocative concentration
of acetylcholine which produced a 20% fall in FEV1
（mgml) (PC20) was measured in each subject (see
below). Sputum induction was performed 15 minutes
after recovery from the acetylcholine challenge test.
Acetylcholine challenge does not affect sputum re-
sults.8
MEASUREMENT OF EXHALED NITRIC OXIDE
(NO) CONCENTRATION
The concentrations of exhaled nitric oxide were
measured according to the guidelines of the Ameri-
can Thoracic Society ( ATS ) by the single-breath
method (on-line measurement) using a fast response
( 0.02 S ) chemiluminescence analyzer ( NOA 280 ;
Sievers Instruments Inc., Boulder, CO, USA).9 While
seated, the subjects breathed through a mouthpiece
attached to a one-way valve. The valve had two sam-
pling ports near the mouthpiece. NO was sampled di-
rectly into the analyzer through a Teflon side-arm
tube attached to one of the sampling ports. The exha-
lation pressure was measured by a pressure trans-
ducer in the analyzer via the second sampling port.
All measurements were made using a mouth pres-
sure of 16 cmH2O corresponding to an expiratory
flow of 75 mls. After inhalation to TLC, the subjects
immediately exhaled into the mouthpiece. The mouth
pressure was then displayed on a computer screen as
a prompt for the subjects to maintain a steady flow.
NO values were recorded as a plateau at the last part
of the exhalation . Repeated exhalations were per-
formed to achieve three NO values that agreed at the
5% level. NO concentrations were recorded as the av-
erage of these three values. Values of 20 parts per bil-
lion (ppb) and above were judged to be abnormal.
MEASUREMENT OF FLOW-VOLUME CURVES
Forced vital capacity, FEV1, maximal expiratory flow
at 50% and at 25% were measured with a spirometer
(Superspiro, DISCOM-21FX, Chest M.I. Co., Tokyo,
Japan). Results were expressed as percentage of pre-
dicted, based on relevant reference standards.10
MEASUREMENT OF SERUM IgE-RIST AND IgE-
RAST
Venous blood was obtained and serum IgE-RIST was
measured using fluoroenzyme immunoassay (FEIA)
(CAP RIST FEIA, Pharmacia, Uppsala, Sweden). Se-
rum IgE-RAST was measured using FEIA ( CAP
RAST FEIA, Pharmacia)．
MEASUREMENT OF AIRWAY HYPERRESPON-
SIVENESS TO ACETYLCHOLINE
The challenge test was performed using the method
of Makino et al. 11 All antiasthma medications were
withheld for at least 48 hrs before measurement of
airway hyperresponsiveness. Subjects inhaled acetyl-
choline aerosol from a hand-held nebulizer (Clinical
air pump, model REB 30REPC-Medicare 24, Medi-
care Co., Yokohama, Japan) by tidal breathing for 2
min. The operating airflow rate was 5 lmin. The iso-
tonic saline was inhaled first as a control. This was
followed by doubling concentrations of acetylcholine
from 0.039 to 20 mgml. The FEV1 was measured af-
ter each inhalation with a spirometer (Superspiro ,
DISCOM-21FX, Chest M.I. Co., Tokyo, Japan). The
percentage FEV1 fall was calculated from the post
saline-FEV1. The test was continued until the FEV1
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Fig. 2　The time course of exhaled nitric oxide concentrations in the BUD and MK groups. The exhaled nitric ox-
ide concentrations of the BUD group (n = 15) were significantly lowered after 1 and 6 months of treatment com-
pared to pretreatment level, but did not return to normal level. The MK group (n = 12) had similar results. *P < 0.05
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had fallen > 20% or until the maximal concentration of
acetylcholine had been administered. The airway hy-
perresponsiveness was expressed as PC20. At the
end of the test, any fall in FEV1 was reversed with an
inhalation of salbutamol (0.3 ml of Venetlin for inha-
lation). Subjects with PC20 of less than 8 mgml were
considered to have airway hyperresponsiveness ac-
cording to the criteria of the American Thoracic Soci-
ety.10
SPUTUM INDUCTION AND PROCESSING
Sputum Induction
Sputum was induced by inhalation of 5 ml of 3% NaCl
solution, using a small ultrasonic nebulizer ((NE-U12,
OMRON Co., Tokyo, Japan). The output is about 5 L
min and the mean aerodynamic mass median diame-
ters of the nebulized saline solution range from 1 to 5
μm, according to the manufacturer. Before coughing
up sputum , subjects were asked to rinse their
mouths , swallow saliva and water , and blow their
noses , to minimize contamination with saliva and
post-nasal drip . Subjects were asked cough during
and after inhalation, and to expectorate into empty
containers. Induction was discontinued once an ade-
quate sputum sample had been obtained or 30 min-
utes had passed. Inhaled β2-stimulant (2 ml of saline
and 0.3 ml of salbutamol solution with pressurized
nebulizer) was premedicated. To check lung func-
tion , flow-volume curve measurements were made
before and after sputum induction . If FEV1.0 de-
creased by more than 10%, the subject was treated
with additional inhalation of β2-stimulant. None of the
subjects experienced marked adverse effects．
Sputum Processing
Sputum was processed within 30 minutes . It was
stored in a refrigerator at + 4℃ pending processing.
Sputum samples were transferred to a Petri dish and
the more viscous parts collected using forceps. Spu-
tum plugs were first mixed with forceps. The samples
were processed by a method described by Metso et
al.12 to collect cells for cytospin and cell-free superna-
tant. A four-fold volume of 6.5 mmolL dithiothreitol
(DTT) (SputolysinR, CalbioChem, LaJolla, California,
USA ; diluted 10-fold in distilled water) was added to
the sputum sample and the mixture was incubated for
15 minutes on a roller mixer at room temperature. An
equal volume of phosphate-buffered saline (PBS, pH
7.2) was added, and incubation continued for another
five minutes. The mixture was filtered through a 53
μm mesh nylon filter (Nybolt PA-5335, Seidengaze,
Germany). Sputum cells were separated by centrifu-
gation at 2000 g for 10 minutes and the supernatant
was collected for fluid-phase markers. Cells obtained
after centrifugation were resuspended in 1 ml of PBS
and the total number of cells was determined using a
haemocytometer. Viability was measured by means
of the trypan blue exclusion test (trypan blue stain
0.4%, GibcoBRL Life Tchnologies, UK). The cell sus-
pension was cytocentrifuged (Cytospin 3, Shandon,
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Fig. 3　The time course of PC20 in the BUD and MK groups. The values of logPC20 in the both groups 
were not significantly improved after 1 and 6 months of treatment compared to pretreatment level.
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Astmoor, UK) on to microscope slides (Super FrostR
Plus, Menzel-Glaser, Germany) at 450 rpm for six
minutes. Cytospins from sputum were allowed to dry
in the air for 30 minutes and were then stained using
the Giemsa stain method. Reagents were from Muto
Pure Chemicals Co., Ltd, Tokyo, Japan. At least 400
non-squamous cells , including eosinophils , neutro-
phils, lymphocytes, macrophages and ciliated epithe-
lial cells were counted differentially. Results were ex-
pressed as percentages of total non- squamous
counts . If examination of slides revealed macro-
phages and ciliated epithelial cells, the sample was
considered to be of bronchial origin and was included
in the study. Cytospin slides for immunocytochemis-
try were processed immediately , or wrapped and
stored at − 80℃ (at least two weeks) prior to fixation
and permeabililization. It was confirmed that there is
no effects of freezing and thawing on immunocyto-
chemical results.
Data Analysis
The values of lung function are expressed as mean ±
standard deviation. Data of logPC20, exhaled nitric
oxide concentration and sputum eosinophil ratio are
expressed as mean (95% confidence interval (CI)).
Differences were analyzed using Willcoxon signed
rank test with the level of significance (p-value) set at
0.05．
RESULTS
EXHALED NITRIC OXIDE CONCENTRATION ,
PC20 AND SPUTUM EOSINOPHIL RATIO OF ALL
PATIENTS
The pretreatment values of exhaled nitric oxide con-
centration, PC20 and sputum eosinophil ratio were
117 ± 95 ppb, 2.60 ± 0.59 mgml, and 13.1 ± 14.5%, re-
spectively, for the 27 patients with mild intermittent
asthma. Airway inflammation was certainly present
even in these patients and the level of airway hyperre-
sponsiveness was elevated (Fig. 1).
TIME COURSE OF EXHALED NITRIC OXIDE
CONCENTRATIONS IN THE BUD AND MK
GROUPS
Before the treatment, no significant difference in ex-
haled nitric oxide concentrations was found between
the BUD group and the MK group. The concentra-
tions of the BUD group were 122 ± 89 ppb before the
start of treatment, 60 ± 32 ppb after 1 month of treat-
ment and 46 ± 24 ppb after 6 months of treatment.
For the MK group, the concentrations were 112 ± 66
ppb before treatment, 78 ± 46 ppb after 1 month of
treatment and 40 ± 18 ppb after 6 months of treat-
ment. The exhaled nitric oxide concentrations were
similarly lowered by treatment in both groups but not
to the normal level . Degree of improvement meas-
ured by the reduction of exhaled nitric oxide concen-
tration did not differ between the two groups accord-
ing to analysis by unpaired t-test (Fig. 2).
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Fig. 4　The time course of sputum eosinophil ratio in the BUD and MK groups. The ratios of eosinophils in 
the sputum of the BUD group (n = 15) were significantly lowered after 1 and 6 months of treatment compared 
to pretreatment level, but did not return to the normal level. The ratios of eosinophils in the sputum of the MK 
group (n = 12) were significantly lowered after 6 months of treatment compared to pretreatment level, but did 
not return to the normal level.
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TIME COURSE OF PC20 IN THE BUD AND MK
GROUPS
There was no difference in pre-treatment PC20 be-
tween the BUD group and the MK group. The values
of logPC20 for the BUD group were 2.47 ± 0.58 be-
fore treatment, 2.67 ± 0.47 after 1 month of treatment
and 2.86 ± 0.52 after 6 months of treatment. For the
MK group, these values were 2.76 ± 0.57 before treat-
ment, 2.94 ± 0.71 after 1 month of treatment and 3.11
± 0.62 after 6 months of treatment. In both groups,
the values of logPC20 were not significantly improved
after treatment (Fig. 3).
TIME COURSE OF THE SPUTUM EOSINOPHIL
RATIOS IN THE BUD AND MK GROUPS
Before the treatment , the percentage of sputum
eosinophils did not differ between the BUD group
and the MK group. Ratio in the BUD group were 14.5
± 14.1% before treatment, 7.1 ± 9.9% after 1 month of
treatment and 4.7 ± 5.8% after 6 months of treatment.
The ratios in the MK group were 11.4 ± 9.2% before
treatment, 6.3 ± 5.3% after 1 month of treatment 3.9 ±
2.2% after 6 months of treatment. The ratios of eosino-
phils were similarly improved but not to the normal
level. The degrees of improvement in the percentage
of sputum eosinophils did not differ between the two
groups according to the analysis with the unpaired t-
test (Fig. 4).
DISCUSSION
According to guideline1 of GINA 2002, anti-inflam-
matory therapy is not necessary for mild intermittent
asthma (step 1), but in the Japanese guidelines13 the
use of a minimum dose of inhaled steroids is recom-
mended. In the present study, the factor principally
responsible for the elevation of airway hyperrespon-
siveness in mild asthma appeared to be eosinophilic
inflammation, and if this is left untreated, it could in-
duce airway remodeling and ultimately intractable
asthma. It is generally believed that in asthma pa-
tients the longer the disease continues, the more re-
modeling of the airways, thickening of the basement
membranes and hyperresponsiveness increase.
Obase et al. reported, in a study of asthma patients
who outgrew their condition, that the duration of in-
fantile asthma is correlated with the duration of air-
way hyperresponsiveness and also with airway in-
flammation.14 Although it is difficult to reverse struc-
tural changes which have been established as a result
of advanced airway remodeling, it is quite likely that
airway remodeling can be prevented by early intro-
duction of anti-inflammatory treatment . Therefore ,
early intervention , i . e ., starting anti-inflammatory
treatment in the early stage of development of asthma
at step 1, is desirable．
Selroos et al. and Agertoft et al. reported that the
introduction of inhaled steroid treatment in the early
phase of development of asthma resulted in signifi-
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cant improvement of respiratory function . 15,16 Haa-
htela et al. reported that early introduction of inhaled
steroid treatment improved airway hyperresponsive-
ness.17 These reports showed that respiratory func-
tion and hyperresponsiveness of patients whose dura-
tion of asthma was short responded well to inhaled
steroids and that improvement was minimal in pa-
tients whose duration of asthma was long. Pauwels et
al. reported in the inhaled steroids as regular therapy
in early asthma (START) study that long-term ad-
ministration of low-dose budesonide to patients with
mild persistent asthma who had suffered from the
disease for not longer than 2 years reduced the risk
of asthma exacerbation and improved the control of
asthm.18 Sullivan et al. reported in the START study
that early administration of budesonide reduced ab-
sence from school and lessened negative effects on
work , and that the cost-effectiveness ratio of this
treatment was also good.19 There is a study of inhaled
steroids and a leukotriene receptor antagonist for the
airway inflammation in patients with step 1 and 2 mild
asthma,20 but data of patients with mild intermittent
asthma (step 1) treated by leukotriene receptor an-
tagonist alone have not been available . There is a
clinical study by Kemp et al. on the effect of montelu-
kast on exercise induced asthma in children with age
of 6 to 14 years, but, in that study, only selective num-
ber of patients could fit in the category of patients
with mild and intermittent type asthma.21 Moreover,
in their study, the short term effect (2 crossover peri-
ods of 2 days) of the leukotriene receptor antagonist
for challenge induced asthma was discussed in pa-
tients with mild intermittent asthma ; the aim was not
the same as that of this long term study.
In the present study, a conclusion was drawn from
the results of the 6-month long-term treatment , in
which early intervention of anti-inflammatory treat-
ment was found to be necessary for patients with
mild and intermittent asthma (step 1). In this study
we did not analyze data from the point of view of dis-
ease duration because of the limited number of pa-
tients ; however , it appears that , even at step 1,
lengthening of duration of asthma due to lack of or in-
sufficient treatment leads to persistent airway inflam-
mation and change of airway structures, i.e., remodel-
ing, resulting in persistent elevation of airway hyper-
responsiveness. Therefore, it appears possible to nor-
malize airway hyperresponsiveness by treatment of
airway inflammation at an early phase of development
of asthma. The present study was not conducted with
comparison with placebo. Yet, we concluded that the
improvement in airway inflammation was due to the
treatment effects, but not the natural course of recov-
ery process because we selected patients who had
stable (step 1) asthma without attacks as subjects of
the study , and those patients remained stable
throughout the study period. In fact, those patients
were in stable phase of asthma (step 1) according to
patient diaries and measurements of peak flow ; no
symptoms, use of inhaled β2 stimulant as needed and
no changes in peak flow, and their asthma symptoms
were well controlled during this study. The aim of
this study was to evaluate the treatment for airway in-
flammation in stable step 1 asthmatic patients without
asthma attacks . However , there were patients in-
cluded in this study who received β2-stimulant alone,
and those cases will be reported in the future . Al-
though the definitions of cure and remission of
asthma have not been clearly established, our study
has indicated that most asthma patients who outgrew
their disease have persistent airway inflammation and
airway hyperresponsiveness,14 and that there is a risk
of asthma recurrence even if patients have had no
symptoms for 10 years or longer. The patients in step
1 of the present study have levels of airway inflamma-
tion and airway hyperresponsiveness similar to those
who outgrew their disease and, therefore, it is possi-
ble that their asthma symptoms will reappear in the
future.
There is no doubt that anti-inflammatory treatment
is now important in asthma therapy. Currently , in-
haled steroids are the best medications, as safe and
efficacious anti-inflammatory drugs that can be used
for a long period of time. Reports published thus far
have all suggested that prevention of airway remodel-
ing is possible with the early introduction of inhaled
steroid therapy. However, the present study revealed
that , though it was difficult to distinguish the re-
sponder group from the non-responder group, leuko-
toriene receptor antagonist was also effective against
step 1 asthma．
The main cause of increase in airway hyperrespon-
siveness is airway inflammation. Airway inflammation
can be evaluated by collecting sputum induced by in-
haled hyperosmotic NaCl solution and analyzing its
cell and supernatant components. By determining the
level of airway inflammation by measuring the num-
ber of eosinophils in induced sputum, ECP and cy-
tokines, it is also possible to examine the relationship
of airway inflammation with increases in airway hy-
perresponsiveness. Our plan for the future is to meas-
ure ECP and cytokines in the supernatant of sputum
of these patients , perform immunostaining of the
cells in sputum and investigate the cells that produce
these substances. By testing the sputum induced by
inhaled hyperosmotic NaCl solution and by introduc-
ing anti-inflammatory treatment while asthma is still
at an early stage or is mild, it will be possible to im-
prove airway hyperresponsiveness, prevent remodel-
ing , prevent progression of disease to intractable
asthma and, possibly, attain cure of asthma in certain
cases．
In conclusion, even in mild intermittent asthma, ex-
haled nitric oxide concentrations and sputum eosino-
phil ratios were elevated and airway inflammation
was clearly present. Airway hyperresponsiveness was
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also elevated. The effects of low-dose inhaled steroid
and leukotriene receptor antagonist in improving air-
way inflammationwere almost the same. Therefore,
to prevent remodeling and disease progression to se-
vere or intractable asthma, early introduction of anti-
inflammatory treatment is necessary even in cases of
mild intermittent asthma. We believe that either of
the two types of medications, i .e., low-dose inhaled
steroids and leukotriene receptor antagonists, can be
chosen as anti-inflammatory drugs for mild intermit-
tent asthma．
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